Compare the evidence

Sources, findings and their limits
Source and designPopulation or scopeFindingLimits
Official Propodine label [1]Dog CYP2B11 warning; separate opioid and premedication passagesDistinguishes reduced clearance, altered anesthetic requirements and cardiorespiratory depression.These endpoints are different; the dog enzyme statement is not a direct feline finding.
Martinez et al., 2024 — genetic survey and recombinant experiments [2]Canine P450 oxidoreductase/CYP2B11 experimental systemCertain variants reduced propofol oxidation in the experimental system.In vivo confirmation needed; no ketoconazole co-administration or recovery-time measurement.
Grubb et al., 2020 — AAHA anesthesia guideline [3]Care before, during and after anesthesiaProvides a framework for medication review and recovery assessment within the whole plan.Abstract reviewed; no fixed ketoconazole-related propofol correction.

Can another medicine change recovery from propofol anesthesia?

Yes. Propodine describes changes in anesthetic requirements and recovery with other medicines. Its interaction section links medicines including ketoconazole to reduced clearance and prolonged recovery; it does not predict an individual animal's recovery time. [1]

What is the ketoconazole-related warning in dogs?

Propodine names dog CYP2B11 and lists ketoconazole, chloramphenicol and loperamide in its reduced-clearance and prolonged-recovery warning. The dog-specific enzyme wording should remain attached to that claim, even though the product also covers cats. [1]

Are opioid-related warnings the same as reduced clearance?

No. Propodine separately describes significant respiratory depression and a profound heart-rate decrease with opioids, plus prolonged recovery with some opioid infusions. These effects require assessment alongside, rather than substitution for, the ketoconazole clearance concern. [1]

Does premedication mean the propofol dose will always be the same?

No. Concurrent sedatives or analgesics are likely to reduce induction and maintenance requirements. Propodine directs dosing to individual response; its interaction summary supplies no fixed reduction percentage or public anesthesia protocol. [1]

Does the label give a universal ketoconazole washout time before anesthesia?

No universal ketoconazole washout interval appears in the cited passage. The veterinary team must decide whether medication or procedure timing needs changing from the patient's actual treatment history and anesthetic plan. [1]

What information is most useful before a planned procedure?

Provide current medicines, exact products and routes, recent administrations and previous anesthesia or recovery problems. The team needs the whole regimen to distinguish altered requirements, cardiorespiratory effects and clearance concerns. [1]

Evidence appraisal

Propodine separates effects on anesthetic requirement, cardiorespiratory depression and clearance. These are not interchangeable endpoints: a change in the amount needed for induction does not by itself measure drug elimination, and a recovery observation does not identify which medicine caused it. The ketoconazole passage refers to dog CYP2B11, while the opioid passage separately addresses respiratory depression and decreased heart rate. [1]

A 2024 study by Martinez and colleagues investigated canine P450 oxidoreductase variants using genetic surveys and recombinant enzyme experiments. Certain variants reduced CYP2B11-mediated substrate oxidation, including propofol, in the experimental system; the authors called for in vivo confirmation. This supports attention to the distinction between enzyme activity and patient outcomes. It was not a ketoconazole co-administration trial and cannot predict how many extra minutes a dog will take to recover. [2]

Clinical interpretation and follow-up

The AAHA anesthesia guidelines describe care before, during and after unconsciousness. That framework places medication review and recovery assessment within the whole anesthetic plan. Propodine directs titration to response and notes that premedication can alter requirements; the guideline does not supply a fixed ketoconazole correction. [3] [1]

Provide actual products, routes, administration times, intended anesthetic technique and previous recovery concerns. These editorial review items help distinguish the label's different endpoints. The dedicated ketoconazole article examines the dog clearance warning, supporting enzyme research and the limits of washout predictions. [1] [3]

Questions for veterinary review

Editorial discussion checklist for your veterinarian:

  • Supply the anesthesia team with the complete current medication list, including antifungals and recent sedatives or analgesics.
  • Keep the dog-specific clearance warning distinct from general opioid cardiorespiratory effects.
  • Let the veterinary anesthesia team determine timing, monitoring and the patient-specific plan.

Catalogue review status and evidence limits

The catalogue records contain verified direct evidence (dog): a species-scoped official-label statement, not necessarily a controlled interaction trial. The linked label PDF was also checked for publication.

A verified warning does not establish an individual animal's outcome, a patient-specific dose or independent clinical review. No matching rule does not prove safety.

Evidence sources

Citation scope: official labels support the interaction warnings; research and guidelines provide separately identified context. Each citation shows its document version or literature type and review scope. Catalogue identifiers may refer to earlier versions; this article uses the linked label PDF. Repeated labels are not independent studies. Source URLs and product authorizations may change.

  1. VMD: Propodine 10 mg/ml Emulsion for Injection/Infusion for Dogs and Cats — Summary of Product Characteristics

    Evidence type: Official product label. Unlimited renewal September 2023. 4.8, interactions; 4.9, intravenous administration. Page 4, Page 5. Source checked: . Open official VMD source

  2. Pharmacogenomics of poor drug metabolism in greyhounds: Canine P450 oxidoreductase genetic variation, breed heterogeneity, and functional characterization.

    Martinez SE et al. PLoS One. 2024;19(2):e0297191. Evidence type: Primary study. Review scope: Full text. Source checked: . Open research source

  3. 2020 AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats.

    Grubb T et al. J Am Anim Hosp Assoc. 2020;56(2):59-82. Evidence type: Consensus guideline. Review scope: Abstract and bibliographic record. Source checked: . Open research source

Content responsibility: ZooDDI. For veterinary discussion, not diagnosis, prescribing or emergency care. No independent veterinary clinical review has been completed.

Check a complete medication regimen